GlobeNewswire by notified

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

  • FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21
  • As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2
  • HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide3,4

Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

HS is a chronic, systemic and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body.3 It may take people living with HS an average of up to 10 years to get a correct diagnosis, which can result in disease progression and significantly impact their quality of life.5,6 Until now, there has been only one biologic approved to treat HS.7

“For many patients, the daily impact of HS and the search for symptom relief can last years – which can come with painful, irreversible physical and emotional scarring,” said Alexa B. Kimball, MD, MPH, lead investigator of the SUNSHINE and SUNRISE trials, Professor of Dermatology at Harvard Medical School, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston. “This approval marks an important milestone for countless patients who have been faced with limited treatment possibilities and who now have a new option.”

“HS is one of the most devastating and exhausting skin diseases. The pain of flares can be debilitating and limits my ability to work or participate in social activities. It can have a major impact on me physically and emotionally, including feelings of anxiety, stress and isolation,” said Donna Atherton, EdD, Founder and Chief Mission Officer, International Association of Hidradenitis Suppurativa Network (IAHSN). “The approval of a new treatment option brings fresh hope to me and the HS community that we may find relief from the burden of the disease.”

The FDA approval was based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE, in which a higher proportion of patients given Cosentyx 300 mg either every two weeks or every four weeks achieved a Hidradenitis Suppurativa Clinical Response (HiSCR50) compared to placebo.1 Cosentyx for HS is approved as a 300 mg dose, administered every four weeks, with the option to increase to every two weeks if the patient has an inadequate response.1

In both the SUNSHINE and SUNRISE studies, which evaluated Cosentyx across 16-week (vs placebo) and 52-week treatment periods, the onset of action of Cosentyx occurred as early as Week 2.1 Efficacy progressively increased to Week 16 and was observed up to Week 52.2 The safety profile of Cosentyx observed in these HS trials was consistent with its known safety profile observed in the plaque psoriasis trials, affirming the differentiated safety profile of Cosentyx.1

“Cosentyx can offer effective, lasting relief from HS symptoms so that people with HS have a chance to live every day with confidence,” said Victor Bultó, President, Novartis US. “With this sixth indication approval for Cosentyx – along with ongoing studies in numerous other conditions – we are reaffirming our commitment to reimagine medicine for those living with immunological diseases.”

About the SUNSHINE and SUNRISE trials2
The SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials comprise the largest Phase III program in hidradenitis suppurativa (HS), with a combined enrollment of more than 1,000 patients. SUNSHINE and SUNRISE are identical, global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the short- (16 weeks) and long-term (up to 52 weeks) efficacy, safety and tolerability of two dose regimens of Cosentyx in adults with moderate to severe HS. A Hidradenitis Suppurativa Clinical Response (HiSCR50), the primary endpoint in the two pivotal trials, is defined as at least a 50% decrease in abscess and inflammatory nodule (AN) count with no increase in the number of abscesses and/or draining tunnels. Secondary endpoints included a decrease in abscess and inflammatory nodules by at least 50% (AN50), the proportion of patients experiencing a flare, and the proportion of patients with a skin pain numeric rating scale 30 response up to 16 weeks of treatment.2

Results from the US Food and Drug Administration (FDA)-requested analyses at Week 16 showed that a significantly higher proportion of patients achieved HiSCR50 when treated with Cosentyx 300 mg dosed every two weeks (after standard weekly loading doses), compared with placebo in both the SUNSHINE and SUNRISE trials (44.5% vs 29.4% [*P<0.05] and 38.3% vs 26.1% [*P<0.05], respectively).1 A greater proportion of patients randomized to Cosentyx 300 mg dosed every four weeks (after standard weekly loading doses) achieved HiSCR50 compared with placebo in both SUNSHINE (41.3% vs 29.4%) and SUNRISE (42.5% vs 26.1% [*P<0.05]) trials.1

An exploratory analysis assessed the long-term effects of Cosentyx for each of the primary and secondary endpoints for up to 52 weeks. HiSCR values observed at Week 16 following either dose regimen of Cosentyx were improved over time to Week 52 (SUNSHINE: SECQ2W [56.4%]; SECQ4W [56.3%]; SUNRISE: SECQ2W [65.0%]; SECQ4W [62.2%]), with rapid improvements seen in patients who switched from placebo at Week 16.8

*Statistically significant versus placebo based on the pre-defined hierarchy (from the pre-specified primary statistical analysis) with overall alpha = 0.05 (two-sided).

About Cosentyx® (secukinumab)
Cosentyx is the first and only fully human biologic that specifically targets and blocks interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).9,10 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 8 years of real-world data in adults and 5 years of long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS.11-17 These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA, moderate to severe plaque psoriasis (adult and pediatric) and two subtypes of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis and juvenile psoriatic arthritis.1 More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015.18 Cosentyx is approved in more than 100 countries, most recently gaining approval for JIA and HS in the US and Europe.19,20

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.


  1. Cosentyx Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp; October 2023.
  2. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate to severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and 52 results of two identical, double-blind, placebo-controlled, phase 3 randomised trials. Lancet. 2023; published online Feb 3. Available at: [Last accessed: February 2023].
  3. MedLine Plus. Hidradenitis suppurativa [online]. Available at: [Last accessed: March 2022].
  4. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020;6:18. doi: 10.1038/s41572-020-0149-1
  5. Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology. 2020;236:421-430.
  6. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422-434.
  7. Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clin Cosmet Investig Dermatol. 2023;16:135-148. Published 2023 Jan 19. doi:10.2147/CCID.S391356 4.
  8. Kimball AB, Jemec GBE, Alavi A, et al. Efficacy and Safety of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa from the Phase 3 SUNSHINE and SUNRISE Trials. Poster presented at American Academy of Dermatology (AAD) 2023 Annual Meeting; March 17-21, 2023, New Orleans, LA.
  9. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-24.
  10. McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Annals Rheum Dis. 2019;78:1167-1178.
  11. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005.
  12. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507-1514.
  13. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2:18-25.
  14. Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.
  15. Data on file. CAIN457F2310 and CAIN457F2305 summary of 5-year clinical safety in (ankylosing spondylitis). Novartis Pharmaceuticals Corp; May 2019.
  16. Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008.
  17. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
  18. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; January 2023.
  19. Novartis AG. 2021. Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: [Last accessed: February 2023].
  20. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: [Last accessed: July 2023].

# # #

Novartis Media Relations

Central North America
Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456
Anja von Treskow
Anna Schäfers
+41 79 392 9697
+41 79 801 7267
Michael Meo
Marlena Abdinoor
+1 862 274 5414
+1 617 335 9525
Satoshi Sugimoto +41 79 619 2035
Novartis Investor Relations
Central investor relations line: +41 61 324 7944

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912
Isabella Zinck +41 61 324 7188
To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fujifilm Healthcare Europe partners with R Zero to bring next-gen training simulation technology to European endoscopists29.2.2024 12:36:48 CET | Press release

RATINGEN, Germany, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fujifilm Healthcare Europe GmbH has announced a strategic partnership with R Zero for the exclusive distribution of mikoto, a state-of-the-art endoscopy simulation technology, throughout Europe. This collaboration aims at providing training solutions for endoscopy professionals across the region, to enhance their skills with the intention to improve patient outcomes. As a first step in this partnership, Fujifilm Healthcare Europe will introduce the mikoto colon model to the European market. This advanced and portable medical training simulator enables self-learning by evaluating and scoring procedures using various sensors combined with Artificial intelligence offering four levels of difficulty. In addition to the mikoto colon model, R Zero is currently developing other endoscopic simulators, including upper GI, ERCP, ESD and EMR. These upcoming simulation technologies will provide further training options for endoscopists, allowing

Confirmation of the Offer Period29.2.2024 12:27:53 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU). COMPANY ANNOUNCEMENT Luxembourg, 29 February 2024 Art Share 002 S.A. (“Art Share 002”), confirms that the closing of the offer period in relation to the private placement of up to 550,000 class B shares of Art Share 002 (the “Class B Shares” or the “Offered Shares”) (the “Offering”) and the determination of the aggregate EUR price equivalent for the Offered Share is scheduled for 5 March 2024. Delivery of the Offered Shares against payment of the offer price is expected to take place on 7 March 2024 and trading is expected to commence on or around 8 March 2024. For questions, orders and reques

Auriant Mining AB (publ.) publishes Q4 2023 Interim Report (January - December)29.2.2024 12:20:00 CET | Press release

Highlights 12 months 2023, Auriant Group Amounts in parentheses refer to the same period in the previous year. Gold production in line with the mine plan – 668.3 kg /21,486 oz (780.2 kg /25,082 oz)Gold sales 603.9 kg /19,415 oz (882.2 kg /28,364 oz)Consolidated revenue US$ 37.3 mln (US$ 51.1 mln)Net loss after tax US$ -7.0 mln (profit US$ 7.6 mln)EBITDA US$ 8.4 mln (US$ 15.4 mln)Net cash flow generated from operating activities US$ 4.8 mln (US$ 12.3 mln) Average selling price for gold US$ 1,923 per oz (US$ 1,800 per oz)As of 1 January 2023 the Group changed its functional currency from the US Dollar to Russian Rouble. For all Russian entities the functional currency is the Russian Rouble (RUB). The functional currency of the parent company is Swedish Krona (SEK). The presentation currency is USD (unchanged).In December the terms of the Golden Impala Limited bond were changed as follows: - 12 months grace period on interest accrual was implemented; - the currency of 50% of the total deb

Auriant Mining AB publicerar sin delårsrapport för perioden 1 januari – 31 december 202329.2.2024 12:20:00 CET | Pressemelding

Höjdpunkter under 12 månader 2023, Auriant Group Belopp inom parentes avser samma period föregående år. Guldproduktion är i linje med produktionsplan – 668,3 kg /21 486 oz (780,2 kg /25 082 oz)Guldförsäljningen 603,9 kg /19 415 oz (882,2 kg /28 364 oz)Intäkter 37,3 MUSD (51,1 MUSD)Nettoförlust efter skatt -7,0 MUSD (vinst 7,6 MUSD)EBITDA 8,4 MUSD (15,4 MUSD)Nettokassaflöde från den löpande verksamheten 4,8 MUSD (12,3 MUSD)Genomsnittligt försäljningspris för guld 1 923 USD/oz (1 800 USD/oz)Från och med den 1 januari 2023 ändrade koncernen sin funktionella valuta från US-dollar till ryska rubel. För samtliga ryska enheter är den funktionella valutan ryska rubel (RUB). Moderbolagets funktionella valuta är svenska kronor (SEK). Rapporteringsvalutan är US-dollar (oförändrad).I december ändrades villkoren för obligationen av Golden Impala Limited enligt följande: - 12 månaders anståndstid genomfördes på ränteperioden; - valutan på 50% av den totala skulden omvandlades från USD till SEK. Konc

Key information relating to the cash dividend to be paid by Golar LNG Limited29.2.2024 11:50:30 CET | Press release

Reference is made to the fourth quarter 2023 report released on February 29, 2024. Golar LNG Limited (“Golar”), NASDAQ ticker: GLNG, has declared a total dividend of $0.25 per share to be paid on or around March 20, 2024. The record date will be March 12, 2024. Due to the implementation of the Central Securities Depository Regulation (“CSDR”), please note the information below on the payment date for the small number of Golar shares registered in Norway’s central securities depository (“VPS”): Dividend amount: $0.25 per shareDeclared currency: USD. Dividends payable to shares registered in the VPS will be distributed in NOKLast day including right: March 8, 2024Ex-date: March 11, 2024Record date: March 12, 2024Payment date: On or about March 20, 2024. Due to the implementation of CSDR in Norway, dividends payable to shares registered in the VPS will be distributed on or about March 22, 2024. Golar LNG Limited Hamilton, Bermuda February 29, 2024 This information is subject to the disclo

HiddenA line styled icon from Orion Icon Library.Eye